Research digest / Copper Tripeptide-1
GHK-Cu is a copper tripeptide whose safety record rests on topical cosmetic use, not systemic trials.
A scene-by-scene reading of the GHK-Cu literature: what each study set out to measure, what the copper chemistry bounds, and where the human data stops.
What the GHK-Cu record actually documents
GHK-Cu is the copper(II) complex of glycyl-L-histidyl-L-lysine, a tripeptide the body makes itself. It was first isolated from human plasma by Loren Pickart in 1973 as the factor that made aged liver tissue synthesize protein like younger tissue [6]. The molecule carries two identities at once: a signaling peptide and a copper chaperone. Copper coordination is required for most of its documented activity — the free peptide does not reproduce the same fibroblast effects [3].
The headline finding is matrix synthesis. In human fibroblast cultures, GHK-Cu raised collagen production in a dose-dependent way, with the effect beginning between 10^-12 and 10^-11 M and peaking near 10^-9 M, and crucially without any change in cell number — a specific metabolic effect, not faster cell division [1]. A canonical skin-regeneration review extends that to elastin, glycosaminoglycans, and the proteoglycan decorin, and reports that topical GHK-Cu increased collagen production in 70% of treated women versus 50% for vitamin C and 40% for retinoic acid [3].
The safety story is the reason this site exists. Topical copper tripeptide-1 has a long cosmetic safety record; systemic GHK-Cu does not. No GHK-Cu drug product is FDA-approved for any route [10][11]. That gap — strong topical evidence, absent systemic evidence — is the through-line of every page here. The strongest argument for tolerability is chemical: the complex holds copper with a very high stability constant (log K ~16.4), which limits release of the free, pro-oxidant copper ion [8]. The honest counterweight is that a placebo-controlled post-laser trial found no objective benefit [9], and that most mechanistic data is still in vitro or rodent.
What a copper peptide is
A copper peptide is a short amino-acid chain bound to a copper(II) ion. The binding is what makes it more than the sum of its parts: copper enables lysyl oxidase to cross-link collagen and elastin, drives superoxide-dismutase-like antioxidant chemistry, and is held tightly enough that it does not float free to catalyze damage [7][8]. GHK-Cu is the most-studied example — three amino acids (glycine, histidine, lysine) wrapped around one copper(II) ion in a 1:1 complex, molecular weight 402.92 Da, CAS 89030-95-5.
The form matters. GHK is the free tripeptide (MW 340.38); GHK-Cu is its copper chelate (MW 402.92). Many studies dose the free peptide and report gene-level or systemic effects, while skin-remodeling work uses the copper complex — and because copper coordination is needed for MMP-2 stimulation in fibroblasts, the form a study used is not a footnote, it is the result [3].
GHK copper peptide: what the research describes
The GHK copper peptide is studied across four main territories: skin matrix remodeling, wound repair, hair growth, and antioxidant copper handling. In fibroblasts it stimulates synthesis of collagen, elastin, glycosaminoglycans, and decorin [1][3]. In wound models it raises VEGF, FGF-2, and neurotrophins while suppressing free radicals, thromboxane, TGF-beta-1, and TNF-alpha, and chemoattracts the repair cells that close a wound [6]. In a controlled human hair trial, a 5-aminolevulinic-acid + GHK complex raised hair count significantly over placebo across six months [4].
Gene-expression analysis is where the claims get largest and where caution is highest: GHK is reported to modulate roughly 31.2% of human genes at a 50%-or-greater change threshold, favoring wound-repair, DNA-repair, antioxidant, and ubiquitin-proteasome programs [2]. That signature is striking, but it comes largely from Connectivity Map bioinformatics that still need protein-level human confirmation. The GHK-Cu research findings page walks each territory study by study.
Copper Tripeptide-1 (the INCI name)
Copper Tripeptide-1 is the INCI name — the cosmetic-ingredient label — for GHK-Cu. When a skincare product lists Copper Tripeptide-1, that is the same molecule this site documents under its laboratory name. The distinction is regulatory rather than chemical: as a topical cosmetic ingredient, Copper Tripeptide-1 is legal to market in the US, EU, and UK and carries decades of consumer use; as an injectable or oral systemic agent, GHK-Cu has no approved drug product and no validated human pharmacokinetics [10][11]. The GHK-Cu FDA and regulatory status section sets out that line precisely.
What does a GHK-Cu peptide do?
In research models GHK-Cu stimulates dermal fibroblasts to synthesize collagen, elastin, and glycosaminoglycans and broadly remodels tissue — raising VEGF, FGF-2, and matrix enzymes while suppressing free radicals and inflammatory mediators [6]. The collagen effect is dose-dependent and independent of cell proliferation [1]. Most of this evidence is in vitro and animal; the strongest human data is topical and dermatologic.
What is GHK-Cu and how does it work?
GHK-Cu is the copper(II) chelate of the tripeptide glycyl-histidyl-lysine. It acts as a copper chaperone and a signaling molecule: gene-expression analyses report it modulates roughly 31.2% of human genes at a 50%-or-greater change threshold, favoring wound-repair, DNA-repair, and antioxidant programs [2]. The copper ion also powers cross-linking and antioxidant chemistry that the bare peptide cannot [7].